Epidermal growth factor receptor genotype in plasma DNA and outcome of chemotherapy in the Chinese patients with advanced non-small cell lung cancer

Chinese Medical Journal

Volumn 124, Issue 21, 2011, Pages 3510-3514

  Zhuo, Ming Lei ^a   Wu, Mei Na ^a   Zhao, Jun ^a   Song, Sonya Wei ^b   Bai, Hua ^a   Wang, Shu Hang ^a   Yang, Lu ^a   An, Tong Tong ^a   Wang, Xin ^a   Duan, Jian Chun ^a   Wang, Yu Yan ^a   Guo, Qing Zhi ^a   Liu, Xu Yi ^a   Liu, Ning Hong ^a   Wang, Jie ^a  

^a PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Epidermal growth factor receptor mutation; First line chemotherapy; Gefitinib; Non small cell lung cancer; Plasma; Prognosis; Targeted therapy

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; PLATINUM;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHINESE; DRUG EFFICACY; EXON; FEMALE; GENE MUTATION; GENOTYPE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; SURVIVAL RATE; SURVIVAL TIME; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PLASMIDS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL RATE;

EID: 82255161972     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2011.21.014     Document Type: Article

References (13)

1. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med 2002; 346: 92-98.
2. Sweeney CJ, Zhu J, Sandler AB, Schiller J, Belani CP, Langer C, et al. Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: a phase II trial in patients with metastatic nonsmall cel, lung carcinoma. Cancer 2001; 92: 2639-2647.
3. Sequist LV, Martins RG, Spigel D, Grunberg SM, Spira A, Janne PA, et al. First line Gefitinib in patients with advanced nonsmall-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 2008; 26: 1-8.
4. Pao W, Miller V. Epidermal growth receptor mutations, small-molecule kinase inhibitors, and nonsmall-cell lung cancer. Current knowledge and future directions. J Clin Oncol 2005; 23: 2556-2568.
5. Lee DH, Han JY, Lee HG, Lee JJ, Lee EK, Kim HY, et al. Gefitinib as a first line therapy of advanced of metastatic adenocarcinoma of the lung in never-smokers. Clin Cancer Res 2005; 11: 3032-3037.
6. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. IPASS: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361: 947-957.
7. Kim ES, Hirsh V, Mok T, Socinski MA, Gervais R, Wu YL, et al. Gefitinib versus docetaxel in previously treated nonsmall-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008; 372: 1809-1818.
8. Bai H, Mao L, Wang HS, Zhao J, Yang L, An TT, et al. Epidermal growth factor receptor mutations in plasma DNA samples predict tumour response in Chinese patients with stages IIIB to IV nonsmall-cell lung cancer. J Clin Oncol 2009; 27: 2653-2659.
9. Bell DW, Lynch TJ, Haserlat SM, Harris PL, Okimoto RA, Brannigan BW, et al. Epidermal growth factor receptor mutations and gene amplification in nonsmall-cell lung cancer: molecular analysis of the IDEAL/INTACT Gefitinib Trials. J Clin Oncol 2005; 9: 8081-8092.
10. Herbst RS, Prager D, Hermann R, Fehrenbacher L, Johnson B, Sandler A, et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced nonsmall-cell lung cancer. J Clin Oncol 2005; 23: 5892-5899.
11. Wu M, Zhao J, Song SW, Zhuo M, Wang X, Bai H, et al. EGFR mutations are associated with prognosis but not with the response to first line chemotherapy in the Chinese patients with advanced nonsmall cell, lung cancer. Lung Cancer 2010; 67: 343-347.
12. Pirker R, Pereira JR, Szczesna A, von Pawel J, Krzakowski M, Ramlau R, et al. Cetuximab plus chemotherapy in patients with advanced nonsmall-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009; 373: 1525-1531.
13. Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009; 361: 958-967.